Side effects · People with erosive oral lichen planus
1 finding from 1 review
Oral mucositis (any severity) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (any severity) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone
Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (severe) compared with chlorhexidine mouthwash; GRADE not reported.
1 finding from 1 review
Reduction in pain · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
1 finding from 1 review
Maximal mouth opening (interincisal distance) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes maximal mouth opening (interincisal distance) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
Burning sensation (VAS 0-100) · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
It is very uncertain whether vasodilators (isoxsuprine, xanthinol nicotinate) changes burning sensation (VAS 0-100) compared with placebo or no active treatment (very low certainty).
2 findings from 1 review
MD -51.02 [-72.85, -29.20]
2 studies · 85 participants
Very low
MD -38.79 [-52.06, -25.53]
2 studies · 85 participants
Very low
Adverse effects · People of any age with a confirmed diagnosis, by clinical examination and biopsy, of oral submucous fibrosis (OSF)
1 finding from 1 review
Normalcy of diet (mean worst ability to eat, 1 to 4 scale) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (mean worst ability to eat, 1 to 4 scale) compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
4 findings from 1 review
RR 0.96 [0.88, 1.05]
4 studies · 655 participants
GRADE not reported
Two studies of KGF versus placebo in children were unclear in reporting; no usable data could be presented
2 studies
GRADE not reported
RR 0.95 [0.90, 1.00]
2 studies · 374 participants
GRADE not reported
Show 1 more finding
Number of days in hospital · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in number of days in hospital compared with placebo; GRADE not reported.
1 finding from 1 review
Number of days unable to take medicine orally · Adults with cancer receiving treatment
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to KGF were typically oral-related or skin-related; mostly mild to moderate with very few serious events; reporting poor and inconsistent, not appropriate to meta-analyse (SoF comments cell,…
16 studies
GRADE not reported
Quality of life · Adults with cancer receiving treatment
The review found no eligible studies for this question.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.89 [0.80, 0.99]
6 studies · 852 participants
Low
RR 0.91 [0.83, 1.00]
3 studies · 471 participants
Moderate
RR 0.56 [0.45, 0.70]
4 studies · 344 participants
Moderate
Oral pain · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in oral pain (mean worst pain, 0 to 10 scale) compared with placebo; GRADE not reported.
2 findings from 1 review
Normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube or IV hydration) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube… compared with placebo; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (chemotherapy delays/discontinuations) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (chemotherapy… compared with placebo; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (unscheduled radiotherapy breaks of 5 or more days) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (unscheduled radiotherapy breaks… compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (severe) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (severe) compared with placebo (low certainty).
3 findings from 1 review
RR 0.30 [0.14, 0.65]
3 studies · 263 participants
Low
RR 0.85 [0.65, 1.11]
6 studies · 852 participants
Low
RR 0.79 [0.69, 0.90]
3 studies · 471 participants
High